Altimmune Inc. [ALT] President and CEO makes an insider sale of 20,000 shares worth 400,322.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Altimmune Inc. shares valued at $400,322 were sold by Garg Vipin K on Aug 31. At $20.02 per share, Garg Vipin K sold 20,000 shares. The insider’s holdings dropped to 236,797 shares worth approximately $3.0 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Garg Vipin K sold 15,000 shares, netting a total of over 225,890 in proceeds. Following the sale of shares at $15.06 each, the insider now holds 259,804 shares.

Before that, Roberts M Scot had sold 10,182 shares from its account. In a trade valued at $122,184, the Chief Scientific Officer traded Altimmune Inc. shares for $12.00 each. Upon closing the transaction, the insider’s holdings decreased to 10,182 shares, worth approximately $0.11 million.

Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early June. As of February 11, 2021, Guggenheim has initiated its “Buy” rating for ALT. Earlier on December 14, 2020, Jefferies initiated its rating. Their recommendation was “a Buy” for ALT stock.

Analyzing ALT’s Price Performance

On Wednesday, Altimmune Inc. [NASDAQ: ALT] rose 0.71% to $12.69. The stock’s lowest price that day was $12.25, but it reached a high of $13.55 in the same session. During the last five days, there has been a drop of approximately -14.66%. Over the course of the year, Altimmune Inc. shares have jumped approximately 38.54%. Shares of the company reached a 52-week high of $23.49 on 09/02/22 and a 52-week low of $3.83 on 05/12/22. A 50-day SMA is recorded $15.44, while a 200-day SMA reached $9.35. Nevertheless, trading volume fell to 2.61 million shares from 2.0 million shares the previous day.

Support And Resistance Levels for Altimmune Inc. (ALT)

According to the 24-hour chart, there is a support level at 12.11, which, if violated, would cause prices to drop to 11.53. In the upper region, resistance lies at 13.41. The next price resistance is at 14.13. RSI (Relative Strength Index) is 33.26 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.92, which suggests the price will decrease in the coming days. Percent R is at 87.59%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Altimmune Inc. subject to short interest?

Stocks of Altimmune Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -1.76 million shares to 4.4 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 6.16 million shares. A decline of -40.0% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.31 of the overall float, the days-to-cover ratio (short ratio) decline to 2.31.

Which companies own the most shares of Altimmune Inc. (ALT)?

According to Tang Capital Management LLC filings, the company currently owns 3,600,450 shares, which is about 7.34% of the total ALT shares outstanding. The investor’s shares have appreciated by 1,026,706 from its previous 13-F filing of 2573744.0 shares. With the completion of the sale transaction, TIAA-CREF Investment Management L’s stake is now worth $67,659,302. A total of 1,003,365 shares of Altimmune Inc. were bought by Baker Bros. Advisors LP during the quarter, and -75,163 were sold by The Vanguard Group, Inc. In its current portfolio, Sphera Funds Management Ltd. holds 1,392,884 shares valued at $30.75 million.

In terms of Altimmune Inc. share price expectations, FactSet research, analysts set an average price target of $29.14 in the next 12 months, up nearly 106.35% from the previous closing price of $12.60. Analysts anticipate Altimmune Inc. stock to reach $50.00 by 2022, with the lowest price target being $14.00. In spite of this, 7 analysts ranked Altimmune Inc. stock as a Buy at the end of 2022. On November 12, 2020, B. Riley Securities assigned a price target of “a Buy” to the stock and reiterated coverage with a $28.

LEAVE A REPLY

Please enter your comment!
Please enter your name here